XML 40 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Note A - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Sales, Royalty and Licensing Revenue $ 1,700,000 $ 2,500,000    
Royalty Expense $ 66,000 $ 92,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 0 0    
Share-Based Payment Arrangement, Expense $ 200,000 $ 300,000    
Deferred Compensation Arrangement with Individual, Cash Award Forfeited, Amount 0 $ 0    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net     $ 0 $ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net     0 $ 0
Fair Value, Inputs, Level 1 [Member]        
Fair Value, Net Asset (Liability) 0   0  
Fair Value, Inputs, Level 2 [Member]        
Fair Value, Net Asset (Liability) (1,056,000)   (1,599,000)  
Fair Value, Inputs, Level 2 [Member] | Line of Credit [Member]        
Debt Instrument, Fair Value Disclosure 2,500,000   1,900,000  
Fair Value, Inputs, Level 2 [Member] | Term Loan [Member]        
Debt Instrument, Fair Value Disclosure 8,900,000   8,900,000  
Fair Value, Inputs, Level 3 [Member]        
Fair Value, Net Asset (Liability) $ 0   $ 0  
The 2020 Omnibus Stock Incentive Plan [Member] | Scenario, Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award, Plan Term Extension (Year) 5 years      
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) 550,000      
Restricted Stock [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 170,724 279,792    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 0 0    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) 0 0